These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 35225130)

  • 21. The Psychological Experience of COVID-19 Vaccination and Its Impact on the Willingness to Receive Booster Vaccines among the Chinese Population: Evidence from a National Cross-Sectional Study.
    Miao Y; Li Y; Zhang W; Wu J; Gu J; Wang M; Wei W; Ye B; Miao C; Tarimo CS; Dong W
    Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).
    Meacham PJ; Williams AM; Strawderman M; Baran AM; Archibald WJ; Wallace DS; Tschernia NP; Burack WR; Barr PM; Zent CS
    Leuk Lymphoma; 2020 Jul; 61(7):1636-1644. PubMed ID: 32175786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seroconversion after COVID-19 vaccination and heart transplant recipients: Correspondence.
    Sriwijitalai W; Wiwanitkit V
    Transpl Infect Dis; 2022 Dec; 24(6):e13962. PubMed ID: 36169215
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
    Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
    BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
    Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
    J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with Solid Tumors Seroconvert after SARS-CoV-2 mRNA Vaccine.
    Cancer Discov; 2021 Sep; 11(9):2122. PubMed ID: 34272229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Shen Y; Freeman JA; Holland J; Solterbeck A; Naidu K; Soosapilla A; Downe P; Tang C; Kerridge I; Wallman L; Van Bilsen N; Milogiannakis V; Akerman A; Martins Costa Gomes G; Sandgren K; Cunningham AL; Turville S; Mulligan SP
    Br J Haematol; 2022 Apr; 197(1):41-51. PubMed ID: 34962656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 30. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose.
    Rossi AH; Ojeda DS; Varese A; Sanchez L; Gonzalez Lopez Ledesma MM; Mazzitelli I; Alvarez Juliá A; Oviedo Rouco S; Pallarés HM; Costa Navarro GS; Rasetto NB; Garcia CI; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Sosa S; Bianchimano L; Rios AS; Treffinger Cienfuegos MS; Caramelo JJ; Longueira Y; Laufer N; Alvarez DE; Carradori J; Pedrozza D; Rima A; Echegoyen C; Ercole R; Gelpi P; Marchetti S; Zubieta M; Docena G; Kreplak N; Yanovsky M; Geffner J; Pifano M; Gamarnik AV
    Cell Rep Med; 2021 Aug; 2(8):100359. PubMed ID: 34308389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
    Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).
    Tran AP; Tassone D; Nossent J; Ding NS
    RMD Open; 2022 May; 8(1):. PubMed ID: 35577478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
    Corti C; Antonarelli G; Scotté F; Spano JP; Barrière J; Michot JM; André F; Curigliano G
    Ann Oncol; 2022 Feb; 33(2):158-168. PubMed ID: 34718117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?
    Giné E; Bosch F; Villamor N; Rozman M; Colomer D; López-Guillermo A; Campo E; Montserrat E
    Leukemia; 2002 Aug; 16(8):1454-9. PubMed ID: 12145685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
    Larkin HD
    JAMA; 2022 Jun; 327(23):2280. PubMed ID: 35727270
    [No Abstract]   [Full Text] [Related]  

  • 37. A booster with SARS-CoV-2 vaccines: protection against Omicron infection.
    Hu Y; Sun Q
    Signal Transduct Target Ther; 2022 Apr; 7(1):115. PubMed ID: 35383164
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19 mRNA Vaccine Booster During Pregnancy Increases Maternal and Fetal Antibodies.
    Abbasi J
    JAMA; 2022 Jul; 328(2):120-121. PubMed ID: 35731542
    [No Abstract]   [Full Text] [Related]  

  • 39. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.
    Marasco V; Carniti C; Guidetti A; Farina L; Magni M; Miceli R; Calabretta L; Verderio P; Ljevar S; Serpenti F; Morelli D; Apolone G; Ippolito G; Agrati C; Corradini P
    Br J Haematol; 2022 Feb; 196(3):548-558. PubMed ID: 34649298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications.
    Levit E; Longbrake EE; Stoll SS
    Mult Scler Relat Disord; 2022 Apr; 60():103719. PubMed ID: 35276450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.